BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32526919)

  • 1. Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity.
    Hajeri PB; Sharma NS; Yamamoto M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replicating adenoviruses in cancer therapy.
    Dobbelstein M
    Curr Top Microbiol Immunol; 2004; 273():291-334. PubMed ID: 14674605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
    Sato-Dahlman M; Yamamoto M
    Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenoviruses for the treatment of brain tumors.
    Gomez-Manzano C; Fueyo J
    Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
    Hoffmann D; Wildner O
    BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
    Schierer S; Hesse A; Müller I; Kämpgen E; Curiel DT; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2008 Jan; 122(1):219-29. PubMed ID: 17764070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
    Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
    J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
    Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.
    Sato-Dahlman M; LaRocca CJ; Yanagiba C; Yamamoto M
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenoviruses for treatment of brain tumours.
    Dirven CM; van Beusechem VW; Lamfers ML; Grill J; Gerritsen WR; Vandertop WP
    Expert Opin Biol Ther; 2002 Dec; 2(8):943-52. PubMed ID: 12517272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of transcriptionally regulated oncolytic adenoviruses.
    Ko D; Hawkins L; Yu DC
    Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
    Cervera-Carrascon V; Havunen R; Hemminki A
    Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.
    van Erp EA; Kaliberova LN; Kaliberov SA; Curiel DT
    Mol Ther Oncolytics; 2015; 2():15001. PubMed ID: 27119101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors.
    Ahmed AU; Ulasov IV; Mercer RW; Lesniak MS
    Methods Mol Biol; 2012; 797():97-109. PubMed ID: 21948472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
    Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
    Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.